198 related articles for article (PubMed ID: 19081789)
1. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing.
Humbert M; Rasmussen RA; Ong H; Kaiser FM; Hu SL; Ruprecht RM
PLoS One; 2008; 3(12):e3937. PubMed ID: 19081789
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
3. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
[TBL] [Abstract][Full Text] [Related]
4. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
Leaman DP; Lee JH; Ward AB; Zwick MB
J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
8. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.
Kraft Z; Strouss K; Sutton WF; Cleveland B; Tso FY; Polacino P; Overbaugh J; Hu SL; Stamatatos L
J Virol; 2008 Jun; 82(12):5912-21. PubMed ID: 18400850
[TBL] [Abstract][Full Text] [Related]
9. Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail.
Samal S; Das S; Boliar S; Qureshi H; Shrivastava T; Kumar N; Goswami S; Bansal M; Chakrabarti BK
Retrovirology; 2018 Jul; 15(1):50. PubMed ID: 30029604
[TBL] [Abstract][Full Text] [Related]
10. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
12. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
13. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
15. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
16. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
18. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
19. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
Mouquet H; Klein F; Scheid JF; Warncke M; Pietzsch J; Oliveira TY; Velinzon K; Seaman MS; Nussenzweig MC
PLoS One; 2011; 6(9):e24078. PubMed ID: 21931643
[TBL] [Abstract][Full Text] [Related]
20. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]